Bristol Myers Squibb Revenue Growth Rates (BMY), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bristol myers Squibb Company  (NYSE: BMY)
 

BMY's Revenue Growth by Quarter and Year

Bristol Myers Squibb's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BMY Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 12,973.00
1st Quarter March 11,489.00
FY 24,462.00

BMYs Annual Revenue
Bristol Myers Squibb's Revenue in the fiscal year 2025 $ 48,194.00 millions
Bristol Myers Squibb's Revenue in the fiscal year 2024 $ 48,300.00 millions
Bristol Myers Squibb's Revenue in the fiscal year 2023 $ 45,006.00 millions
Bristol Myers Squibb's Revenue in the fiscal year 2022 $ 46,159.00 millions
Bristol Myers Squibb's Revenue in the fiscal year 2021 $ 46,385.00 millions




BMY Revenue second quarter 2026 Y/Y Growth Comment
Bristol myers Squibb Company achieved in the second quarter 2026, above Company average Revenue improvement of 5.74% year on year, to $ 12,973.00 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 114 other companies have achieved higher Revenue growth. While Bristol Myers Squibb Company' s Revenue increase of 5.74% ranks overall at the positon no. 2180 in the second quarter 2026.


BMY Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 1.3 % 7.54 % 0.62 %
3rd Quarter September - 2.77 % 8.44 % -2.25 %
2nd Quarter June 5.74 % 0.56 % 8.69 % -5.56 %
1st Quarter March 2.57 % -5.6 % 4.66 % -2.67 %
FY   - -0.22 % 7.32 % -

Financial Statements
Bristol Myers Squibb's second quarter 2026 Revenue $ 12,973.00 millions BMY's Income Statement
Bristol Myers Squibb's second quarter 2025 Revenue $ 12,269.00 millions Quarterly BMY's Income Statement


BMY Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 2.29 % 3.78 % 4.66 %
3rd Quarter September - -0.38 % -2.53 % -2.32 %
2nd Quarter June 12.92 % 9.53 % 2.83 % -0.98 %
1st Quarter March -8.1 % -9.24 % 3.38 % -0.6 %
FY (Year on Year)   - -0.22 % 7.32 % -


Back to BMY Growth rate Comparisons >> Back to BMY Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #115
Healthcare Sector #321
Overall #2180

Revenue Y/Y Growth Statistics
High Average Low
82.11 % 5.58 % -30.1 %
(Sep 30 2020)   (March 31, 2013)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #115
Healthcare Sector #321
Overall #2180
Revenue Y/Y Growth Statistics
High Average Low
82.11 % 5.58 % -30.1 %
(Sep 30 2020)   (March 31, 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Bristol Myers Squibb's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
35.7 % 1.36 % -15.91 %
(Mar 31 2020)  


BMY's II. Quarter Q/Q Revenue Comment
Bristol myers Squibb Company achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.92%, to $ 12,973.00 millions, from $11,489.00 millions in the first quarter.
BMY is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Bristol Myers Squibb's Revenue growth quarter on quarter, overall rank is 709.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #709
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #119
Overall #709
Revenue Q/Q Growth Statistics
High Average Low
35.7 % 1.36 % -15.91 %
(Mar 31 2020)  


BMY's II. Quarter Q/Q Revenue Comment
Bristol myers Squibb Company achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.92%, to $ 12,973.00 millions, from $11,489.00 millions in the first quarter.
BMY is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Bristol Myers Squibb's Revenue growth quarter on quarter, overall rank is 709.


Bristol Myers Squibb's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 49,186.00 $ 48,482.00 $ 48,194.00 $ 48,034.00 $ 47,704.00
Y / Y Revenue Growth (TTM) 3.11 % 1.78 % -0.22 % 1.26 % 2.57 %
Year on Year Revenue Growth Overall Ranking # 2360 # 735 # 1464 # 745 # 1741
Seqeuential Revenue Change (TTM) 1.45 % 0.6 % 0.33 % 0.69 % 0.14 %
Seq. Revenue Growth (TTM) Overall Ranking # 2625 # 2593 # 2044 # 2004 # 1826


Cumulative Revenue growth Comment
Although Bristol Myers Squibb's Annual Revenue growth year on year were below company's average 5.33% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.11% year on year, from 1.78% in Mar 31 2026.

In the Healthcare sector 339 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 735 to 2360.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 340
Overall # 2360

Revenue TTM Y/Y Growth Statistics
High Average Low
62.97 %
 5.33 %
-24.59 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 375
S&P 500 # 2625
Cumulative Revenue growth Comment
Although Bristol Myers Squibb's Annual Revenue growth year on year were below company's average 5.33% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.11% year on year, from 1.78% in Mar 31 2026.

In the Healthcare sector 339 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 735 to 2360.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 340
Overall # 2360

Revenue TTM Y/Y Growth Statistics
High Average Low
62.97 %
5.33 %
-24.59 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 375
S&P 500 # 2625




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BMY's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Concentra Group Holdings Parent Inc 10.03%$ 10.030 millions
Lemaitre Vascular Inc 10.02%$ 10.017 millions
Amneal Pharmaceuticals Inc 9.93%$ 9.934 millions
Merit Medical Systems Inc9.79%$ 9.792 millions
Idexx Laboratories Inc9.73%$ 9.728 millions
Lenz Therapeutics Inc 9.72%$ 9.720 millions
Encompass Health Corporation9.58%$ 9.584 millions
Trisalus Life Sciences Inc 9.57%$ 9.567 millions
Amgen Inc 9.53%$ 9.533 millions
Sotera Health Company9.45%$ 9.452 millions
Illumina Inc 9.44%$ 9.443 millions
Stryker Corp9.42%$ 9.415 millions
International Stem Cell Corporation9.32%$ 9.318 millions
Cytosorbents Corporation9.29%$ 9.292 millions
Resmed Inc 9.22%$ 9.222 millions
Fate Therapeutics Inc 9.18%$ 9.177 millions
Bausch and Lomb Corp9.08%$ 9.077 millions
Pacs Group Inc 9.07%$ 9.071 millions
Electromed Inc 8.97%$ 8.968 millions
National Healthcare Corp8.83%$ 8.833 millions
Chemed Corporation8.80%$ 8.800 millions
Tactile Systems Technology Inc 8.76%$ 8.763 millions
Gyre Therapeutics Inc 8.72%$ 8.718 millions
P3 Health Partners Inc 8.60%$ 8.599 millions
Maravai Lifesciences Holdings Inc 8.53%$ 8.534 millions
U S Physical Therapy Inc8.47%$ 8.470 millions
Ocugen Inc 8.38%$ 8.376 millions
Baxter International Inc 8.36%$ 8.363 millions
Carlisle Companies Incorporated8.33%$ 8.334 millions
Universal Health Services Inc 8.27%$ 8.268 millions


About Bristol Myers Squibb Revenue Growth Rates (BMY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bristol Myers Squibb Co (CIK 14272).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000014272-26-000020
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bristol Myers Squibb Co’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.